Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Waldenström Macroglobulinemia Specialty Channel

News
Cyclophosphamide and Rituximab With Bortezomib Highly Effective for Patients With Treatment-Naive Waldenström Macroglobulinemia
04/01/2024

Jordan Kadish

Jordan Kadish
Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.
Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.
Cyclophosphamide and rituximab...
04/01/2024
Oncology
Quiz
Efficacy of Sequential Treatment Escalation Among Patients With Waldenström Macroglobulinemia
02/26/2024
02/26/2024
Oncology
News
Sequential Treatment Escalation May Extend Survival for Patients With Waldenström Macroglobulinemia
02/14/2024

Amber Denham

Amber Denham
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation...
02/14/2024
Oncology
Quiz
Comparing Outcomes of Zanubrutinib Versus Ibrutinib for Waldenström Macroglobulinemia
02/02/2024
True or False: Findings from a final analysis of the phase 3 ASPEN trial indicated that zanubrutinib exhibited similar efficacy and improved safety and tolerability compared to ibrutinib among patients with Waldenström macroglobulinemia,...
True or False: Findings from a final analysis of the phase 3 ASPEN trial indicated that zanubrutinib exhibited similar efficacy and improved safety and tolerability compared to ibrutinib among patients with Waldenström macroglobulinemia,...
True or False: Findings from a...
02/02/2024
Oncology
Quiz
B-DRC Combination Treatment for Waldenström Macroglobulinemia
05/30/2023
According to findings from a trial assessing the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide (B-DRC) as a first-line combination treatment for Waldenström macroglobulinemia, the median time to first response was ___ in...
According to findings from a trial assessing the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide (B-DRC) as a first-line combination treatment for Waldenström macroglobulinemia, the median time to first response was ___ in...
According to findings from a...
05/30/2023
Oncology
News
B-DRC Combination Treatment Yielded High Response Rates Among Patients With Waldenström Macroglobulinemia
04/19/2023

Jordan Kadish

Jordan Kadish
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the...
04/19/2023
Oncology
Quiz
Quiz: Zanubrutinib Versus Ibrutinib for Waldenström Macroglobulinemia
03/21/2023
True or False: According to findings of the phase 3 ASPEN trial, zanubrutinib yielded higher complete response rates and advantages in long-term safety versus ibrutinib among patients with Waldenström macroglobulinemia.
True or False: According to findings of the phase 3 ASPEN trial, zanubrutinib yielded higher complete response rates and advantages in long-term safety versus ibrutinib among patients with Waldenström macroglobulinemia.
True or False: According to...
03/21/2023
Oncology
News
Venetoclax Safe, Effective in Previously Treated Patients With Waldenström Macroglobulinemia
06/26/2022
Study findings suggest venetoclax is safe and effective in previously treated patients with WM, including those previously exposed to BTK inhibitors.
Study findings suggest venetoclax is safe and effective in previously treated patients with WM, including those previously exposed to BTK inhibitors.
Study findings suggest...
06/26/2022
Oncology
News
Ibrutinib Plus Rituximab for Waldenström Macroglobulinemia: Final Results From the iNNOVATE Trial
05/13/2022

John Otrompke

John Otrompke
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab...
05/13/2022
Oncology
News
Zanubrutinib Well Tolerated, Exhibits Consistent Safety Profile in Patients With B-Cell Malignancies
04/07/2022

John Otrompke

John Otrompke
According to a pooled analysis of data, zanubrutinib monotherapy for patients with B-cell malignancies is consistent with the toxicity profile of BTK inhibitors.
According to a pooled analysis of data, zanubrutinib monotherapy for patients with B-cell malignancies is consistent with the toxicity profile of BTK inhibitors.
According to a pooled analysis...
04/07/2022
Oncology
Computer
Quiz
Quiz: Does Ibrutinib Induce Durable Responses in Patients With WM?
04/05/2022
True or false: A phase 2 trial found that ibrutinib monotherapy induces high rates of durable responses in patients with WM.
True or false: A phase 2 trial found that ibrutinib monotherapy induces high rates of durable responses in patients with WM.
True or false: A phase 2 trial...
04/05/2022
Oncology

Advertisement

News

News
Cyclophosphamide and Rituximab With Bortezomib Highly Effective for Patients With Treatment-Naive Waldenström Macroglobulinemia
04/01/2024

Jordan Kadish

Jordan Kadish
Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.
Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.
Cyclophosphamide and rituximab...
04/01/2024
Oncology
News
Sequential Treatment Escalation May Extend Survival for Patients With Waldenström Macroglobulinemia
02/14/2024

Amber Denham

Amber Denham
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation...
02/14/2024
Oncology
News
B-DRC Combination Treatment Yielded High Response Rates Among Patients With Waldenström Macroglobulinemia
04/19/2023

Jordan Kadish

Jordan Kadish
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the...
04/19/2023
Oncology
News
Venetoclax Safe, Effective in Previously Treated Patients With Waldenström Macroglobulinemia
06/26/2022
Study findings suggest venetoclax is safe and effective in previously treated patients with WM, including those previously exposed to BTK inhibitors.
Study findings suggest venetoclax is safe and effective in previously treated patients with WM, including those previously exposed to BTK inhibitors.
Study findings suggest...
06/26/2022
Oncology
News
Ibrutinib Plus Rituximab for Waldenström Macroglobulinemia: Final Results From the iNNOVATE Trial
05/13/2022

John Otrompke

John Otrompke
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab...
05/13/2022
Oncology
News
Zanubrutinib Well Tolerated, Exhibits Consistent Safety Profile in Patients With B-Cell Malignancies
04/07/2022

John Otrompke

John Otrompke
According to a pooled analysis of data, zanubrutinib monotherapy for patients with B-cell malignancies is consistent with the toxicity profile of BTK inhibitors.
According to a pooled analysis of data, zanubrutinib monotherapy for patients with B-cell malignancies is consistent with the toxicity profile of BTK inhibitors.
According to a pooled analysis...
04/07/2022
Oncology
News
Treatment of Patients With R/R WM With Ixazomib Appears Safe and Effective
03/30/2022

John Otrompke

John Otrompke
Treatment of patients with R/R WM with the oral proteasome inhibitor ixazomib combined with subcutaneous rituximab was associated with a median duration of response of 36 months.
Treatment of patients with R/R WM with the oral proteasome inhibitor ixazomib combined with subcutaneous rituximab was associated with a median duration of response of 36 months.
Treatment of patients with R/R...
03/30/2022
Oncology
News
No Statistically Significant Impact of CXCR4 Mutations on Efficacy of Ibrutinib in WM
03/21/2022

John Otrompke

John Otrompke
Ibrutinib is a standard-of-care first line therapy for patients with WM. However, long-term follow-up results from a phase 2 trial found that for patients with WM treated with ibrutinib monotherapy, none experienced a complete response.
Ibrutinib is a standard-of-care first line therapy for patients with WM. However, long-term follow-up results from a phase 2 trial found that for patients with WM treated with ibrutinib monotherapy, none experienced a complete response.
Ibrutinib is a standard-of-care...
03/21/2022
Oncology
News
MYD88 Mutation, Other Distinguishing Characteristics May Help Identify WM
03/08/2022

John Otrompke

John Otrompke
MYD88 mutation and increased IgM peak levels help to distinguish WM from other indolent B-cell malignancies. In the study, the MYD88 mutation was found in almost all WM cases.
MYD88 mutation and increased IgM peak levels help to distinguish WM from other indolent B-cell malignancies. In the study, the MYD88 mutation was found in almost all WM cases.
MYD88 mutation and increased IgM...
03/08/2022
Oncology
News
Post-Transplant Ibrutinib Associated With Longer Survival in Twice-Relapsed WM
03/01/2022
Almost half of post-relapse WM patients relapse again following auto-HCT, according to findings from a recent study.
Almost half of post-relapse WM patients relapse again following auto-HCT, according to findings from a recent study.
Almost half of post-relapse WM...
03/01/2022
Oncology

Interactive Features

Quiz
Efficacy of Sequential Treatment Escalation Among Patients With Waldenström Macroglobulinemia
02/26/2024
02/26/2024
Oncology
Quiz
Comparing Outcomes of Zanubrutinib Versus Ibrutinib for Waldenström Macroglobulinemia
02/02/2024
True or False: Findings from a final analysis of the phase 3 ASPEN trial indicated that zanubrutinib exhibited similar efficacy and improved safety and tolerability compared to ibrutinib among patients with Waldenström macroglobulinemia,...
True or False: Findings from a final analysis of the phase 3 ASPEN trial indicated that zanubrutinib exhibited similar efficacy and improved safety and tolerability compared to ibrutinib among patients with Waldenström macroglobulinemia,...
True or False: Findings from a...
02/02/2024
Oncology
Quiz
B-DRC Combination Treatment for Waldenström Macroglobulinemia
05/30/2023
According to findings from a trial assessing the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide (B-DRC) as a first-line combination treatment for Waldenström macroglobulinemia, the median time to first response was ___ in...
According to findings from a trial assessing the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide (B-DRC) as a first-line combination treatment for Waldenström macroglobulinemia, the median time to first response was ___ in...
According to findings from a...
05/30/2023
Oncology
Quiz
Quiz: Zanubrutinib Versus Ibrutinib for Waldenström Macroglobulinemia
03/21/2023
True or False: According to findings of the phase 3 ASPEN trial, zanubrutinib yielded higher complete response rates and advantages in long-term safety versus ibrutinib among patients with Waldenström macroglobulinemia.
True or False: According to findings of the phase 3 ASPEN trial, zanubrutinib yielded higher complete response rates and advantages in long-term safety versus ibrutinib among patients with Waldenström macroglobulinemia.
True or False: According to...
03/21/2023
Oncology
Computer
Quiz
Quiz: Does Ibrutinib Induce Durable Responses in Patients With WM?
04/05/2022
True or false: A phase 2 trial found that ibrutinib monotherapy induces high rates of durable responses in patients with WM.
True or false: A phase 2 trial found that ibrutinib monotherapy induces high rates of durable responses in patients with WM.
True or false: A phase 2 trial...
04/05/2022
Oncology
blood cell
Quiz
Quiz: What is Post-Transplant Ibrutinib Associated With in WM?
03/07/2022
True or false: The median post-relapse OS is longer in patients with WM who received ibrutinib following an auto-HCT.
True or false: The median post-relapse OS is longer in patients with WM who received ibrutinib following an auto-HCT.
True or false: The median...
03/07/2022
Oncology
blood cell
Test Your Knowledge
Quiz: Is the CXCR4 Mutation Associated With Worse PFS for Patients With WM?
02/25/2022
True or false: CXCR4 mutations are associated with a lower chance of major and deep responses, as well as worse PFS, in patients with WM treated with ibrutinib therapy.
True or false: CXCR4 mutations are associated with a lower chance of major and deep responses, as well as worse PFS, in patients with WM treated with ibrutinib therapy.
True or false: CXCR4 mutations...
02/25/2022
Oncology
stethoscope
Test Your Knowledge
Quiz: Did the iNNOVATE Study Confirm Ibrutinib Plus Rituximab Efficacy for WM?
02/03/2022
True or false: Results of the double-blind, randomized, phase 3 iNNOVATE study confirmed the sustained efficacy of ibrutinib plus rituximab in patients with WM.
True or false: Results of the double-blind, randomized, phase 3 iNNOVATE study confirmed the sustained efficacy of ibrutinib plus rituximab in patients with WM.
True or false: Results of the...
02/03/2022
Oncology
health care
Test Your Knowledge
Quiz: Are Advances in WM, LPL Associated With Rituximab?
02/03/2022
Fill in the blank: A population-based study on patients with WM and LPL found the 5-year relative survival (RS) rate significantly ______ over time with the introduction of rituximab in the early-mid 2000s.
Fill in the blank: A population-based study on patients with WM and LPL found the 5-year relative survival (RS) rate significantly ______ over time with the introduction of rituximab in the early-mid 2000s.
Fill in the blank: A...
02/03/2022
Oncology
medical
Test Your Knowledge
Quiz: What Therapy has Similar Outcomes to Bendamustine-Rituximab for WM?
01/31/2022
True or false: In contrast to prior studies, data from a real-world population-based analysis of frontline therapy found RCVP and BR had similar outcomes in patients with TN WM.
True or false: In contrast to prior studies, data from a real-world population-based analysis of frontline therapy found RCVP and BR had similar outcomes in patients with TN WM.
True or false: In contrast to...
01/31/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Cyclophosphamide and Rituximab With Bortezomib Highly Effective for Patients With Treatment-Naive Waldenström Macroglobulinemia
04/01/2024

Jordan Kadish

Jordan Kadish
Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.
Cyclophosphamide and rituximab with bortezomib demonstrated high efficacy and tolerability among patients with treatment-naive Waldenström macroglobulinemia, according to a phase 2 trial.
Cyclophosphamide and rituximab...
04/01/2024
Oncology
News
Sequential Treatment Escalation May Extend Survival for Patients With Waldenström Macroglobulinemia
02/14/2024

Amber Denham

Amber Denham
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation...
02/14/2024
Oncology
News
B-DRC Combination Treatment Yielded High Response Rates Among Patients With Waldenström Macroglobulinemia
04/19/2023

Jordan Kadish

Jordan Kadish
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the use of bortezomib-dexamethasone, rituximab, and cyclophosphamide as a first-line combination treatment was safe and increased response rates among patients with Waldenström macroglobulinemia.
According to a recent trial, the...
04/19/2023
Oncology
News
Venetoclax Safe, Effective in Previously Treated Patients With Waldenström Macroglobulinemia
06/26/2022
Study findings suggest venetoclax is safe and effective in previously treated patients with WM, including those previously exposed to BTK inhibitors.
Study findings suggest venetoclax is safe and effective in previously treated patients with WM, including those previously exposed to BTK inhibitors.
Study findings suggest...
06/26/2022
Oncology
News
Ibrutinib Plus Rituximab for Waldenström Macroglobulinemia: Final Results From the iNNOVATE Trial
05/13/2022

John Otrompke

John Otrompke
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab significantly reduces risk of disease progression or death over rituximab alone for patients with Waldenström macroglobulinemia.
Ibrutinib added to rituximab...
05/13/2022
Oncology
News
Zanubrutinib Well Tolerated, Exhibits Consistent Safety Profile in Patients With B-Cell Malignancies
04/07/2022

John Otrompke

John Otrompke
According to a pooled analysis of data, zanubrutinib monotherapy for patients with B-cell malignancies is consistent with the toxicity profile of BTK inhibitors.
According to a pooled analysis of data, zanubrutinib monotherapy for patients with B-cell malignancies is consistent with the toxicity profile of BTK inhibitors.
According to a pooled analysis...
04/07/2022
Oncology
News
Treatment of Patients With R/R WM With Ixazomib Appears Safe and Effective
03/30/2022

John Otrompke

John Otrompke
Treatment of patients with R/R WM with the oral proteasome inhibitor ixazomib combined with subcutaneous rituximab was associated with a median duration of response of 36 months.
Treatment of patients with R/R WM with the oral proteasome inhibitor ixazomib combined with subcutaneous rituximab was associated with a median duration of response of 36 months.
Treatment of patients with R/R...
03/30/2022
Oncology
News
No Statistically Significant Impact of CXCR4 Mutations on Efficacy of Ibrutinib in WM
03/21/2022

John Otrompke

John Otrompke
Ibrutinib is a standard-of-care first line therapy for patients with WM. However, long-term follow-up results from a phase 2 trial found that for patients with WM treated with ibrutinib monotherapy, none experienced a complete response.
Ibrutinib is a standard-of-care first line therapy for patients with WM. However, long-term follow-up results from a phase 2 trial found that for patients with WM treated with ibrutinib monotherapy, none experienced a complete response.
Ibrutinib is a standard-of-care...
03/21/2022
Oncology
News
MYD88 Mutation, Other Distinguishing Characteristics May Help Identify WM
03/08/2022

John Otrompke

John Otrompke
MYD88 mutation and increased IgM peak levels help to distinguish WM from other indolent B-cell malignancies. In the study, the MYD88 mutation was found in almost all WM cases.
MYD88 mutation and increased IgM peak levels help to distinguish WM from other indolent B-cell malignancies. In the study, the MYD88 mutation was found in almost all WM cases.
MYD88 mutation and increased IgM...
03/08/2022
Oncology
News
Post-Transplant Ibrutinib Associated With Longer Survival in Twice-Relapsed WM
03/01/2022
Almost half of post-relapse WM patients relapse again following auto-HCT, according to findings from a recent study.
Almost half of post-relapse WM patients relapse again following auto-HCT, according to findings from a recent study.
Almost half of post-relapse WM...
03/01/2022
Oncology
News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement